The EMPAVR randomized clinical trial will investigate the clinical effects of empagliflozin in patients following aortic valve replacement.
This paper describes the design and rationale of the EMPAVR randomized clinical trial evaluating empagliflozin after aortic valve replacement.
Absolute Event Rate: 0% vs 0%
The EMPAVR study was registered in December 2024 (Clinical Trial Registration number: NCT06171802) before enrollment of the first patient. All patients will provide oral and written informed consent. The EMPAVR study is approved by the Regional Committee on Health Research Ethics and the Danish Medicines Agency.
Sørensen et al. (Sun,) reported a other. The EMPAVR randomized clinical trial will investigate the clinical effects of empagliflozin in patients following aortic valve replacement.